EVANSTON, Illinois — The rye plant, a cereal crop widely grown for its grain, has held a secret for nearly 30 years. On its pollen, researchers discovered two unusual molecules that appeared to slow tumor growth in animal studies. The finding was tantalizing.
But the work stalled. Scientists could not figure out the exact three-dimensional shapes of those molecules, a fundamental puzzle that kept the potential therapy locked away.
Now, chemists at Northwestern University have cracked it. By building the molecules from scratch in the laboratory, they have confirmed the precise structures of secalosides A and B for the first time. The breakthrough, published in the Journal of the American Chemical Society, hands researchers a molecular blueprint.
With that map in hand, they can finally begin asking how these compounds from rye pollen interact with the immune system. “In preliminary studies, other researchers found that rye pollen could help different animal models clear tumors through some unknown, non-toxic mechanism,” said Karl A.
Scheidt, the Northwestern chemist who led the study. “Now that we confirmed the structure of these molecules, we can find the active ingredient.” The story begins nearly 30 years ago. Scientists spotted these molecules in rye pollen and saw they had unusual biological activity.
Tumors in lab animals shrank. Yet the research hit a wall. Without knowing the molecules’ exact architecture, no one could synthesize them in meaningful quantities.
No one could run controlled experiments to understand how they worked. The project sat, dormant, for decades.
Scheidt’s team at Northwestern took a different approach. Instead of extracting tiny, impure samples from rye pollen, they built the molecules from the ground up using synthetic chemistry. The payoff came when the team matched their lab-built molecules to the natural ones.
The structures were identical. For the first time, researchers have a reliable, reproducible source of secalosides A and B.
They can now hand these molecules to immunologists and cancer biologists to test. What makes these molecules stand out, according to the study, is the hint of a non-toxic mechanism. Many cancer treatments — chemotherapy, radiation — work by poisoning rapidly dividing cells.
They are brutal on the body. The early rye pollen studies suggested something different: the molecules appeared to help the animals’ own immune systems clear tumors. No toxicity was reported.
That distinction is critical. If secalosides work by rallying the immune system rather than poisoning cells, they could open a new avenue for cancer therapy with fewer side effects.
The Northwestern study does not prove that yet. But it provides the foundation. The study, published in the Journal of the American Chemical Society, is a chemistry paper at its core.
It reports the synthesis and structural confirmation of secalosides A and B. But the implications reach far beyond the lab bench.
With the molecular structure confirmed, researchers can now screen these compounds against a range of immune cells to see exactly what they do. “Now that we confirmed the structure of these molecules, we can find the active ingredient,” Scheidt said. That search for the active ingredient is the next step.
The rye pollen likely contains a cocktail of compounds. Secalosides A and B are two of them. There may be others.
The Northwestern team has given scientists a way to isolate and test each one. The work also opens the door to chemical modifications.
Once you know the structure of a molecule, you can tweak it — change a side chain here, add a functional group there — to make it more potent, more stable, or more selective. Medicinal chemists can now design analogs of secalosides and test them in parallel. None of this was possible when the molecules were first discovered.
The technology to solve complex natural product structures has advanced dramatically in the last three decades. Crystallography, nuclear magnetic resonance spectroscopy, and synthetic chemistry methods have all improved.
Northwestern’s team brought those tools to bear on a problem that had long seemed intractable. The study is published. The structures are confirmed.
The next phase belongs to biologists and immunologists. They will take these molecules and put them into cell-based assays, then into animal models, to understand the mechanism of action. The goal is to determine exactly how secalosides interact with the immune system to fight tumors.
Scheidt and his team have laid the groundwork. The field now has a reliable synthetic route to produce secalosides A and B in the lab.
That means researchers can get the quantities they need for rigorous testing. It means the work is reproducible. It means the stalled research from 30 years ago can finally move forward.
The rye plant, a humble cereal crop, may hold a key to immune-based cancer therapies. But that is a long road.
The Northwestern study is a foundational step, not a finished drug. It answers a basic scientific question that had blocked progress for decades. With that question answered, the real work can begin. Consult your doctor for medical advice.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Northwestern Chemists Solve 30-Year Rye Pollen Mystery, Paving Way”, “description”: “EVANSTON, Illinois — The rye plant, a cereal crop widely grown for its grain, has held a secret for nearly 30 years. On its pollen,…”, “datePublished”: “2026-07-07T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Isabella Moore”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
